| Pharmaceutical Information |
| Drug Name |
Denileukin diftitox |
| Drug ID |
BADD_D00607 |
| Description |
A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. |
| Indications and Usage |
For treatment of cutaneous T-cell lymphoma |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XX29 |
| DrugBank ID |
DB00004
|
| KEGG ID |
D03682
|
| MeSH ID |
C078456
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| UNII |
25E79B5CTM
|
| Synonyms |
denileukin diftitox | Ontak | LY-335348 | DAB(389)-interleukin 2 | DAB389-IL-2 | DAB(389)-IL-2 | DAB(389)IL-2 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
173146-27-5 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
